The muscarinic system, cognition and schizophrenia

Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine

Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156 · see citing works

Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the ‘‘right stuff’’?

Green, M. F., Kern, R. S., Braff, D. L., & Mintz, J. (2000) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033430 · Cited by 2,999 · see citing works

Dementia Praecox and Paraphrenia.

(1972) · Annals of Internal Medicine · doi:10.7326/0003-4819-76-6-1058_8 · Cited by 2,906 · see citing works

Schizophrenia

van Os, J., & Kapur, S. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60995-8 · Cited by 1,971 · see citing works

Cholinergic innervation of cortex by the basal forebrain: Cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (Substantia innominata), and hypothalamus in the rhesus monkey

Mesulam, M. ‐., Mufson, E. J., Levey, A. I., & Wainer, B. H. (1983) · Journal of Comparative Neurology · doi:10.1002/cne.902140206 · Cited by 1,962 · see citing works

Identification of a Family of Muscarinic Acetylcholine Receptor Genes

Bonner, T. I., Buckley, N. J., Young, A. C., & Brann, M. R. (1987) · Science · doi:10.1126/science.3037705 · Cited by 1,427 · see citing works

Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS

Green, M. F., Kern, R. S., & Heaton, R. K. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.09.009 · Cited by 1,422 · see citing works

Identification of separable cognitive factors in schizophrenia

Nuechterlein, K. H., Barch, D. M., Gold, J. M., Goldberg, T. E., Green, M. F., & Heaton, R. K. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.09.007 · Cited by 1,304 · see citing works

Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial

Keefe, R. S. E. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.6.633 · Cited by 1,072 · see citing works

The Effects of Clozapine, Risperidone, and Olanzapine on Cognitive Function in Schizophrenia

Meltzer, H. Y., & McGurk, S. R. (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033376 · Cited by 1,022 · see citing works

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs

Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988 · see citing works

Neuronal nicotinic receptors: from structure to pathology

Gotti, C., & Clementi, F. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.09.006 · Cited by 970 · see citing works

Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies

Levey, A. I., Kitt, C. A., Wf, S., Price, D., & Brann, M. R. (1991) · Journal of Neuroscience · doi:10.1523/jneurosci.11-10-03218.1991 · Cited by 920 · see citing works

Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor

Kubo, T., Fukuda, K., Mikami, A., Maeda, A., Takahashi, H., Mishina, M., Haga, T., Haga, K., Ichiyama, A., Kangawa, K., et al. (1986) · Nature · doi:10.1038/323411a0 · Cited by 896 · see citing works

Brain nicotinic acetylcholine receptors: native subtypes and their relevance

Gotti, C., Zoli, M., & Clementi, F. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.07.004 · Cited by 882 · see citing works

Schizophrenia

Mueser, K. T., & McGurk, S. R. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16458-1 · Cited by 876 · see citing works

Schizophrenia Is a Cognitive Illness: Time for a Change in Focus

Kahn, R. S., & Keefe, R. S. E. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.155 · Cited by 825 · see citing works

Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes

Bonner, T. I., Young, A. C., Brann, M. R., & Buckley, N. J. (1988) · Neuron · doi:10.1016/0896-6273(88)90190-0 · Cited by 783 · see citing works

Determinants of Real-World Functional Performance in Schizophrenia Subjects: Correlations With Cognition, Functional Capacity, and Symptoms

Bowie, C. R., Reichenberg, A., Patterson, T. L., Heaton, R. K., & Harvey, P. D. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.3.418 · Cited by 764 · see citing works

Prefrontal Dopamine D₁Receptors and Working Memory in Schizophrenia

Abi-Dargham, A., Mawlawi, O., Lombardo, I., Gil, R., Martinez, D., Huang, Y., Hwang, D.-R., Keilp, J., Kochan, L., Van Heertum, R., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-09-03708.2002 · Cited by 724 · see citing works

The validity of scopolamine as a pharmacological model for cognitive impairment: A review of animal behavioral studies

Klinkenberg, I., & Blokland, A. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.04.001 · Cited by 714 · see citing works

Effects of Xanomeline, a Selective Muscarinic Receptor Agonist, on Cognitive Function and Behavioral Symptoms in Alzheimer Disease

Bodick, N. C., Offen, W., Levey, A. I., Cutler, N. R., Gauthier, S. G., Satlin, A., Shannon, H. E., Tollefson, G. D., Rasmussen, K., Bymaster, F. P., et al. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550160091022 · Cited by 687 · see citing works

Unraveling the attentional functions of cortical cholinergic inputs: interactions between signal-driven and cognitive modulation of signal detection

Sarter, M., Hasselmo, M. E., Bruno, J. P., & Givens, B. (2005) · Brain Research Reviews · doi:10.1016/j.brainresrev.2004.08.006 · Cited by 667 · see citing works

A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia

Woodward, N. D., Purdon, S. E., Meltzer, H. Y., & Zald, D. H. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114570500516x · Cited by 605 · see citing works

Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia

Shekhar, A., Potter, W. Z., Lightfoot, J., Lienemann, J., Dubé, S., Mallinckrodt, C. H., Bymaster, F. P., McKinzie, D. L., & Felder, C. C. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.06091591 · Cited by 563 · see citing works

Static and Dynamic Cognitive Deficits in Childhood Preceding Adult Schizophrenia: A 30-Year Study

Reichenberg, A., Caspi, A., Harrington, H., Houts, R., Keefe, R. S. E., Murray, R. M., Poulton, R., & Moffitt, T. E. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09040574 · Cited by 557 · see citing works

Neurocognitive Effects of Clozapine, Olanzapine, Risperidone, and Haloperidol in Patients With Chronic Schizophrenia or Schizoaffective Disorder

Bilder, R. M., GOLDMAN, R. S., Volavka, J., Czobor, P., Hoptman, M. J., Sheitman, B., Lindenmayer, J., Citrome, L., McEvoy, J. P., Kunz, M., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.6.1018 · Cited by 538 · see citing works

Treatment-Resistant Schizophrenia - The Role of Clozapine

Meltzer, H. Y. (1997) · Current Medical Research and Opinion · doi:10.1185/03007999709113338 · Cited by 493 · see citing works

The neural and genetic basis of executive function: Attention, cognitive flexibility, and response inhibition

Logue, S. F., & Gould, T. J. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.08.007 · Cited by 477 · see citing works

Immunological localization of m1–m5 muscarinic acetylcholine receptors in peripheral tissues and brain

Levey, A. I. (1993) · Life Sciences · doi:10.1016/0024-3205(93)90300-r · Cited by 452 · see citing works

Adverse effects of antipsychotic medications.

Muench, J., & Hamer, A. M. (2010) · PubMed · Cited by 427 · see citing works

Clozapine, Olanzapine, Risperidone, and Haloperidol in the Treatment of Patients With Chronic Schizophrenia and Schizoaffective Disorder

Volavka, J., Czobor, P., Sheitman, B., Lindenmayer, J., Citrome, L., McEvoy, J. P., Cooper, T. B., Chakos, M., & Lieberman, J. A. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.2.255 · Cited by 408 · see citing works

Generalized and Specific Neurocognitive Deficits in Prodromal Schizophrenia

Lencz, T., Smith, C. W., McLaughlin, D., Auther, A. M., Nakayama, E. Y., Hovey, L. S., & Cornblatt, B. A. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.09.005 · Cited by 402 · see citing works

How should DSM-V criteria for schizophrenia include cognitive impairment?

Keefe, R. S. E., & Fenton, W. S. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm046 · Cited by 394 · see citing works

Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine

Hagger, C., Buckley, P. F., Kenny, J. T., Friedman, L., Ubogy, D., & Meltzer, H. Y. (1993) · Biological Psychiatry · doi:10.1016/0006-3223(93)90043-d · Cited by 393 · see citing works

Muscarinic Acetylcholine Receptor Knockout Mice: Novel Phenotypes and Clinical Implications

Wess, J. (2004) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.44.101802.121622 · Cited by 381 · see citing works

Evolution of neuropsychological dysfunction during the course of schizophrenia and bipolar disorder

Lewandowski, K. E., Cohen, B. M., & Öngür, D. (2010) · Psychological Medicine · doi:10.1017/s0033291710001042 · Cited by 335 · see citing works

Childhood developmental abnormalities in schizophrenia: evidence from high-risk studies

Niemi, L. T., Suvisaari, J., Tuulio‐Henriksson, A., & Lönnqvist, J. K. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00234-7 · Cited by 321 · see citing works

Characterization of Central Inhibitory Muscarinic Autoreceptors by the Use of Muscarinic Acetylcholine Receptor Knock-Out Mice

Zhang, W., Basile, A. S., Gomeza, J., Volpicelli‐Daley, L. A., Levey, A. I., & Wess, J. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01709.2002 · Cited by 314 · see citing works

Muscarinic receptor subtypes in neuronal and non‐neuronal cholinergic function

Eglen, R. M. (2006) · Autonomic and Autacoid Pharmacology · doi:10.1111/j.1474-8673.2006.00368.x · Cited by 311 · see citing works

Neurocognitive and clinical predictors of functional outcome in patients with schizophrenia and bipolar I disorder at one-year follow-up

Tabarés‐Seisdedos, R., Balanzá‐Martínez, V., Sánchez‐Moreno, J., Martínez‐Arán, A., Salazar-Fraile, J., Selva‐Vera, G., Rubio, C., Mata, I. F., Gómez-Beneyto, M., & Vieta, E. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2007.12.234 · Cited by 301 · see citing works

Human cholinergic basal forebrain: chemoanatomy and neurologic dysfunction

Mufson, E. J., Ginsberg, S. D., Ikonomović, M. D., & DeKosky, S. T. (2003) · Journal of Chemical Neuroanatomy · doi:10.1016/s0891-0618(03)00068-1 · Cited by 295 · see citing works

N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl- d -aspartate receptor activity

Sur, C., Mallorga, P. J., Wittmann, M., Jacobson, M. A., Pascarella, D. M., Williams, J. B., Brandish, P. E., Pettibone, D. J., Scolnick, E. M., & Conn, P. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1835612100 · Cited by 295 · see citing works

Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders

Conn, P. J., Jones, C. K., & Lindsley, C. W. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.12.002 · Cited by 286 · see citing works

Selective activation of the M 1 muscarinic acetylcholine receptor achieved by allosteric potentiation

Ma, L., Seager, M. A., Wittmann, M., Jacobson, M. A., Bickel, D. J., Burno, M., Jones, K., Graufelds, V. K., Xu, G., Pearson, M. S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900903106 · Cited by 282 · see citing works

Localization of m5 muscarinic receptor mRNA in rat brain examined by in situ hybridization histochemistry

Vilaró, M. T., Palacios, J., & Mengod, G. (1990) · Neuroscience Letters · doi:10.1016/0304-3940(90)90064-g · Cited by 269 · see citing works

Projections from basal forebrain to prefrontal cortex comprise cholinergic, GABAergic and glutamatergic inputs to pyramidal cells or interneurons

Henny, P., & Jones, B. E. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06029.x · Cited by 266 · see citing works

Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging

Howes, O. D., Egerton, A., Allan, V., McGuire, P., Stokes, P. R. A., & Kapur, S. (2009) · Current pharmaceutical design · doi:10.2174/138161209788957528 · Cited by 261 · see citing works

The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine

Weiner, D. M., Meltzer, H. Y., Veinbergs, I., Donohue, E. M., Spalding, T. A., Smith, T. T., Mohell, N., Harvey, S. C., Lameh, J., Nash, N. T., et al. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1940-5 · Cited by 253 · see citing works

Novel Selective Allosteric Activator of the M1Muscarinic Acetylcholine Receptor Regulates Amyloid Processing and Produces Antipsychotic-Like Activity in Rats

Jones, C. K., Brady, A. E., Davis, A. A., Xiang, Z., Bubser, M., Tantawy, M. N., Kane, A. S., Bridges, T. M., Kennedy, J. P., Bradley, S. R., et al. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.1850-08.2008 · Cited by 248 · see citing works

A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders

Sendt, K.-V., Tracy, D. K., & Bhattacharyya, S. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2014.11.002 · Cited by 245 · see citing works

Allosteric modulation of the muscarinic M 4 receptor as an approach to treating schizophrenia

Chan, W. Y., McKinzie, D. L., Bose, S., Mitchell, S. N., Witkin, J. M., Thompson, R. C., Christopoulos, A., Lazareno, S., Birdsall, N. J. M., Bymaster, F. P., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800567105 · Cited by 235 · see citing works

Differential Regulation of Molecular Subtypes of Muscarinic Receptors in Alzheimer's Disease

Flynn, D. D., Ferrari-Dileo, G., Mash, D. C., & Levey, A. I. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64041888.x · Cited by 234 · see citing works

Allosteric Modulation of Seven Transmembrane Spanning Receptors: Theory, Practice, and Opportunities for Central Nervous System Drug Discovery

Melancon, B. J., Hopkins, C. R., Wood, M. R., Emmitte, K. A., Niswender, C. M., Christopoulos, A., Conn, P. J., & Lindsley, C. W. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm201139r · Cited by 230 · see citing works

Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation

Crook, J. M., Tomaskovic‐Crook, E., Copolov, D., & Dean, B. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00918-5 · Cited by 228 · see citing works

Development of allosteric modulators of GPCRs for treatment of CNS disorders

Nickols, H. H., & Conn, P. J. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.09.013 · Cited by 227 · see citing works

Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment.

Crook, J., Tomaskovic-Crook, E., Copolov, D., & Dean, B. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.6.918 · Cited by 224 · see citing works

In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia.

Raedler, T., Knable, M., Jones, D. W., Urbina, R. A., Gorey, J. G., Lee, K., Egan, M., Coppola, R., & Weinberger, D. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.1.118 · Cited by 222 · see citing works

Cognitive Functioning in the Schizophrenia Prodrome

Simon, A. E., Cattapan-Ludewig, K., Zmilacher, S., Arbach, D., Gruber, K., Dvorsky, D. N., Roth, B., Isler, E., Zimmer, A., & Umbricht, D. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm018 · Cited by 220 · see citing works

The Cognitive Cost of Anticholinergic Burden: Decreased Response to Cognitive Training in Schizophrenia

Vinogradov, S., Fisher, M., Warm, H., Holland, C. M., Kirshner, M. A., & Pollock, B. G. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09010017 · Cited by 220 · see citing works

Muscarinic Receptor Subtype Pharmacology and Physiology

Eglen, R. M. (2005) · Progress in medicinal chemistry · doi:10.1016/s0079-6468(05)43004-0 · Cited by 212 · see citing works

The cholinergic innervation of the human cerebral cortex.

Mesulam, M.-M. (2004) · Progress in Brain Research · doi:10.1016/s0079-6123(03)45004-8 · Cited by 211 · see citing works

Specificity of Cognitive Deficits in Bipolar Disorder versus Schizophrenia

Daban, C., Martínez‐Arán, A., Torrent, C., Tabarés‐Seisdedos, R., Balanzá‐Martínez, V., Salazar-Fraile, J., Selva‐Vera, G., & Vieta, E. (2006) · Psychotherapy and Psychosomatics · doi:10.1159/000090891 · Cited by 207 · see citing works

Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia

Dean, B., McLeod, M., Keriakous, D., et al. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001199 · Cited by 207 · see citing works

Cholinergic modulation of the cortical neuronal network

Lucas-Meunier, E., Fossier, P., Baux, G., & Amar, M. (2003) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-002-0999-2 · Cited by 207 · see citing works

Centrally Active Allosteric Potentiators of the M4 Muscarinic Acetylcholine Receptor Reverse Amphetamine-Induced Hyperlocomotor Activity in Rats

Brady, A. E., Jones, C. K., Bridges, T. M., Kennedy, J. P., Thompson, A. D., Heiman, J. U., Breininger, M. L., Gentry, P. R., Yin, H., Jadhav, S. B., et al. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.140350 · Cited by 204 · see citing works

The Neurobiology of Cognition in Schizophrenia

Tamminga, C. A. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.0906e11 · Cited by 198 · see citing works

Role of Tegmental Cholinergic Neurons in Dopaminergic Activation, Antimuscarinic Psychosis and Schizophrenia

Yeomans, J. S. (1995) · Neuropsychopharmacology · doi:10.1038/sj.npp.1380235 · Cited by 198 · see citing works

Progressive Changes in the Development Toward Schizophrenia: Studies in Subjects at Increased Symptomatic Risk

Wood, S. J., Pantelis, C., Velakoulis, D., Yücel, M., Fornito, A., & McGorry, P. D. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm149 · Cited by 195 · see citing works

M 4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related central nervous system pathologies

Tzavara, E. T., Bymaster, F. P., Davis, R. J., Wade, M. R., Perry, K. W., Wess, J., McKinzie, D. L., Felder, C. C., & Nomikos, G. G. (2004) · The FASEB Journal · doi:10.1096/fj.04-1575fje · Cited by 191 · see citing works

Physostigmine

Granacher, R. P. (1975) · Archives of General Psychiatry · doi:10.1001/archpsyc.1975.01760210109008 · Cited by 191 · see citing works

Clozapine is a potent and selective muscarinic M4 receptor agonist

Zorn, S. H., Jones, S. B., Ward, K. M., & Liston, D. R. (1994) · European Journal of Pharmacology Molecular Pharmacology · doi:10.1016/0922-4106(94)90047-7 · Cited by 190 · see citing works

Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors.

Shannon, H. E., Bymaster, F. P., Calligaro, D. O., Greenwood, B., Mitch, C. H., Sawyer, B. D., Ward, J. S., Wong, D. T., Olesen, P. H., & Sheardown, M. J. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38667-2 · Cited by 186 · see citing works

Facilitation of Long-Term Potentiation by Muscarinic M1 Receptors Is Mediated by Inhibition of SK Channels

Buchanan, K. A., Petrovic, M. M., Chamberlain, S. E. L., Marrion, N. V., & Mellor, J. R. (2010) · Neuron · doi:10.1016/j.neuron.2010.11.018 · Cited by 184 · see citing works

Molecular cloning and expression of a fifth muscarinic acetylcholine receptor

Liao, C. F., Themmen, A. P. N., Joho, R. H., et al. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)83237-9 · Cited by 181 · see citing works

Molecular Mechanisms of Action and In Vivo Validation of an M4 Muscarinic Acetylcholine Receptor Allosteric Modulator with Potential Antipsychotic Properties

Leach, K., Loiacono, R. E., Felder, C. C., McKinzie, D. L., Mogg, A. J., Shaw, D. B., Sexton, P. M., & Christopoulos, A. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.194 · Cited by 167 · see citing works

Social cognition and neurocognition as predictors of conversion to psychosis in individuals at ultra-high risk

Kim, H. S., Shin, N. Y., Jang, J. H., Kim, E., Shim, G., Park, H. Y., Hong, K. S., & Kwon, J. S. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.04.023 · Cited by 166 · see citing works

Investigation of M1/M4 Muscarinic Receptors in the Anterior Cingulate Cortex in Schizophrenia, Bipolar Disorder, and Major Depression Disorder

Zavitsanou, K., Andrew, K., Mattner, F., & Huang, X. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300367 · Cited by 165 · see citing works

Xanomeline, an M1/M4 preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice

Shannon, H. E., Rasmussen, K., Bymaster, F. P., Hart, J. C., Peters, S. C., Swedberg, M. D. B., Jeppesen, L., Sheardown, M. J., Sauerberg, P., & Fink‐Jensen, A. (2000) · Schizophrenia Research · doi:10.1016/s0920-9964(99)00138-3 · Cited by 165 · see citing works

A Subpopulation of Neuronal M4Muscarinic Acetylcholine Receptors Plays a Critical Role in Modulating Dopamine-Dependent Behaviors

Jeon, J., Dencker, D., Wörtwein, G., Woldbye, D. P. D., Cui, Y., Davis, A. A., Levey, A. I., Schütz, G., Sager, T. N., Mørk, A., et al. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.3843-09.2010 · Cited by 164 · see citing works

An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission

Shirey-Rice, J. K., Xiang, Z., Orton, D., Brady, A. E., Johnson, K. A., Williams, R. D., Ayala, J. E., Rodriguez, A. L., Wess, J., Weaver, D., et al. (2007) · Nature Chemical Biology · doi:10.1038/nchembio.2007.55 · Cited by 161 · see citing works

Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis

Désaméricq, G., Schürhoff, F., Méary, A., Szöke, A., Macquin‐Mavier, I., Bachoud‐Lévi, A., & Maison, P. (2013) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-013-1600-y · Cited by 160 · see citing works

Special Section on Implications of CATIE: What CATIE Found: Results From the Schizophrenia Trial

Swartz, M. S., Stroup, T. S., McEvoy, J. P., Thomas, S., Rosenheck, R. A., Keefe, R. S. E., Hsiao, J., & Lieberman, J. A. (2008) · Psychiatric Services · doi:10.1176/ps.2008.59.5.500 · Cited by 156 · see citing works

Xanomeline and the Antipsychotic Potential of Muscarinic Receptor Subtype Selective Agonists

Mirza, N. R., Peters, D., & Sparks, R. G. (2003) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2003.tb00247.x · Cited by 155 · see citing works

Selective Activation of M4 Muscarinic Acetylcholine Receptors Reverses MK-801-Induced Behavioral Impairments and Enhances Associative Learning in Rodents

Bubser, M., Bridges, T. M., Dencker, D., Gould, R. W., Grannan, M. D., Noetzel, M. J., Lamsal, A., Niswender, C. M., Daniels, J. S., Poslusney, M. S., et al. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500128b · Cited by 155 · see citing works

A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain.

Passik, S. D., Lundberg, J., Kirsh, K. L., Theobald, D., Donaghy, K., Holtsclaw, E., Cooper, M., & Dugan, W. (2002) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(02)00391-3 · Cited by 154 · see citing works

Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia

Scarr, E., Cowie, T., Kanellakis, S., Sundram, S., Pantelis, C., & Dean, B. (2008) · Molecular Psychiatry · doi:10.1038/mp.2008.28 · Cited by 149 · see citing works

Localization of muscarinic M3 receptor protein and M3 receptor binding in rat brain

Levey, A. I., Edmunds, S. M., Heilman, C. J., Desmond, T. J., & Frey, K. A. (1994) · Neuroscience · doi:10.1016/0306-4522(94)90017-5 · Cited by 148 · see citing works

Cellular Signaling Mechanisms for Muscarinic Acetylcholine Receptors

Lanzafame, A. A., Christopoulos, A., & Mitchelson, F. J. (2003) · Receptors and Channels · doi:10.3109/10606820308263 · Cited by 147 · see citing works

Role of dopamine D(2) receptors for antipsychotic activity.

Ginovart, N., & Kapur, S. (2012) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-25761-2_2 · Cited by 145 · see citing works

INITIAL AND FINAL WORK PERFORMANCE IN SCHIZOPHRENIA: COGNITIVE AND SYMPTOM PREDICTORS

BRYSON, G., & BELL, M. D. (2003) · The Journal of Nervous and Mental Disease · doi:10.1097/01.nmd.0000050937.06332.3c · Cited by 138 · see citing works

Antipsychotics in the Treatment of Schizophrenia

Tandon, R. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10075su1.01 · Cited by 137 · see citing works

N-Desmethylclozapine, a Major Metabolite of Clozapine, Increases Cortical Acetylcholine and Dopamine Release In Vivo Via Stimulation of M1 Muscarinic Receptors

Li, Z., Huang, M., Ichikawa, J., Dai, J., & Meltzer, H. Y. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300768 · Cited by 136 · see citing works

The Muscarinic Receptor Agonist Xanomeline Has an Antipsychotic-Like Profile in the Rat

Stanhope, K. J., Mirza, N. R., Bickerdike, M. J., et al. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29291-0 · Cited by 132 · see citing works

Muscarinic and nicotinic receptor modulation of object and spatial -back working memory in humans

GREEN, A., Ellis, K. A., Ellis, J. R., Bartholomeusz, C., ILIC, S., Croft, R. J., LUANPHAN, K., & NATHAN, P. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.04.010 · Cited by 127 · see citing works

Antipsychotic Drug-Like Effects of the Selective M4 Muscarinic Acetylcholine Receptor Positive Allosteric Modulator VU0152100

Byun, N. E., Grannan, M. D., Bubser, M., Barry, R. L., Thompson, A. D., Rosanelli, J., Gowrishankar, R., Kelm, N. D., Damon, S. M., Bridges, T. M., et al. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.2 · Cited by 123 · see citing works

Muscarinic cholinergic hyperactivity in schizophrenia

Tandon, R., Shipley, J. E., Greden, J. F., Mann, N. A., Eisner, W. H., & Goodson, J. A. (1991) · Schizophrenia Research · doi:10.1016/0920-9964(91)90006-d · Cited by 120 · see citing works

The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease.

Bodick, N. C., Offen, W., Shannon, H. E., Satterwhite, J. H., Lucas, R., van Lier, R., & Paul, S. M. (1997) · PubMed · Cited by 113 · see citing works

Relationships Between Cognitive Deficits, Symptoms and Quality of Life in Schizophrenia

Savilla, K., Kettler, L. J., & Galletly, C. A. (2008) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670802050512 · Cited by 112 · see citing works

Should cognitive deficit be a diagnostic criterion for schizophrenia?

Lewis, R. (2004) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0412 · Cited by 109 · see citing works

Altered Hippocampal Muscarinic M4, but Not M1, Receptor Expression from Subjects with Schizophrenia

Scarr, E., Sundram, S., Keriakous, D., & Dean, B. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.08.050 · Cited by 108 · see citing works

Developing treatments for impaired cognition in schizophrenia

Minzenberg, M., & Carter, C. S. (2011) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2011.11.017 · Cited by 102 · see citing works

Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia

Mancama, D. T., Arranz, M. J., Landau, S., et al. (2003) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.20020 · Cited by 101 · see citing works

The potent M1 receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction

Nathan, P. J., Watson, J. M., Jesper, L., Davies, C. H., Peters, G., Dodds, C. M., Swirski, B., Lawrence, P., Bentley, G., O’Neill, B. V., et al. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000752 · Cited by 100 · see citing works

Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice

Woolley, M. L., Carter, H. J., Gartlon, J. E., et al. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.12.020 · Cited by 99 · see citing works

Discovery and Characterization of Novel Subtype-Selective Allosteric Agonists for the Investigation of M1 Receptor Function in the Central Nervous System

Lebois, E. P., Bridges, T. M., Lewis, L. M., Dawson, E. S., Kane, A. S., Xiang, Z., Jadhav, S. B., Yin, H., Kennedy, J. P., Meiler, J., et al. (2009) · ACS Chemical Neuroscience · doi:10.1021/cn900003h · Cited by 99 · see citing works

Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis

Need, A. C., Keefe, R. S. E., Ge, D., Grossman, I., Dickson, S., McEvoy, J. P., & Goldstein, D. B. (2009) · European Journal of Human Genetics · doi:10.1038/ejhg.2008.264 · Cited by 95 · see citing works

α7 Nicotinic acetylcholine receptors and their role in cognition

Lendvai, B., Kassai, F., Szájli, Á., & Némethy, Z. (2012) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2012.11.003 · Cited by 95 · see citing works

Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia

Newell, K. A., Zavitsanou, K., Jew, S. K., & Huang, X. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.07.004 · Cited by 93 · see citing works

Muscarinic m4 receptor activation by some atypical antipsychotic drugs

Zeng, X. P., Le, F., & Richelson, E. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(96)00956-9 · Cited by 93 · see citing works

The Muscarinic M1/M4 Receptor Agonist Xanomeline Exhibits Antipsychotic-Like Activity in Cebus apella Monkeys

Andersen, M. B., Fink‐Jensen, A., Peacock, L., Gerlach, J., Bymaster, F. P., Lundbæk, J. A., & Werge, T. M. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300151 · Cited by 93 · see citing works

Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer's disease and schizophrenia

Rook, J. M., Choi, D., Foster, D. J., & Conn, P. J. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s55104 · Cited by 92 · see citing works

Decreased density of muscarinic receptors in the superior temporal gyrusin schizophrenia

Deng, C., & Huang, X. (2005) · Journal of Neuroscience Research · doi:10.1002/jnr.20600 · Cited by 89 · see citing works

Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting

Navari, R. M. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.08.048 · Cited by 87 · see citing works

Pharmacologic Interactions between the Muscarinic Cholinergic and Dopaminergic Systems in the Modulation of Prepulse Inhibition in Rats

Jones, C. K., Eberle, E. L., Shaw, D. B., et al. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.075887 · Cited by 83 · see citing works

Introduction to Neuropsychopharmacology

Iversen, L. L., Iversen, S. D., Bloom, F. E., et al. (2009) · Oxford University Press eBooks · doi:10.1093/med/9780195380538.003.0009 · Cited by 81 · see citing works

Lorazepam and scopolamine: A single-dose comparison of effects on human memory and attentional processes.

Mintzer, M. Z., & Griffiths, R. R. (2003) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.11.1.56 · Cited by 78 · see citing works

Role of the cholinergic muscarinic system in bipolar disorder and related mechanism of action of antipsychotic agents

Bymaster, F. P., & Felder, C. C. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001019 · Cited by 76 · see citing works

School Performance as a Premorbid Marker for Schizophrenia: A Twin Study

van Oel, C. J., Sitskoorn, M. M., Cremer, M. P. M., & Kahn, R. S. (2002) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006949 · Cited by 73 · see citing works

Decreased cortical muscarinic M1 receptors in schizophrenia are associated with changes in gene promoter methylation, mRNA and gene targeting microRNA

Scarr, E., Craig, J. M., Cairns, M. J., Seo, M. S., Galati, J. C., Beveridge, N. J., Gibbons, A. S., Juzva, S., Weinrich, B., Parkinson-Bates, M., et al. (2013) · Translational Psychiatry · doi:10.1038/tp.2013.3 · Cited by 72 · see citing works

The muscarinic M1 receptor positive allosteric modulator PQCA improves cognitive measures in rat, cynomolgus macaque, and rhesus macaque

Uslaner, J. M., Eddins, D. M., Puri, V., Cannon, C. E., Sutcliffe, J. S., Chew, C. S., Pearson, M. S., Vivian, J. A., Chang, R. K., Ray, W. J., et al. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2788-8 · Cited by 71 · see citing works

AC-260584, an orally bioavailable M1 muscarinic receptor allosteric agonist, improves cognitive performance in an animal model

Bradley, S. R., Lameh, J., Ohrmund, L., Son, T., Bajpai, A., Nguyen, D., Friberg, M., Burstein, E. S., Spalding, T. A., Ott, T. R., et al. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.10.003 · Cited by 68 · see citing works

Agonist activation of transfected human M1 muscarinic acetylcholine receptors in CHO cells results in down-regulation of both the receptor and the α subunit of the G-protein Gq

Mullaney, I., Dodd, M. W., Buckley, N. J., et al. (1993) · Biochemical Journal · doi:10.1042/bj2890125 · Cited by 68 · see citing works

Chemical lead optimization of a pan Gq mAChR M1, M3, M5 positive allosteric modulator (PAM) lead. Part I: Development of the first highly selective M5 PAM

Bridges, T. M., Kennedy, J. P., Cho, H. P., Breininger, M. L., Gentry, P. R., Hopkins, C. R., Conn, P. J., & Lindsley, C. W. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.11.089 · Cited by 67 · see citing works

Widespread decreases in cortical muscarinic receptors in a subset of people with schizophrenia

Gibbons, A. S., Scarr, E., Boer, S., Money, T., Jeon, W. J., Felder, C. C., & Dean, B. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000028 · Cited by 67 · see citing works

Effect of anticholinergics on positive and negative symptoms in schizophrenia.

Tandon, R., DeQuardo, J. R., Goodson, J. A., et al. (1992) · PubMed · Cited by 66 · see citing works

Involvement of a Subpopulation of Neuronal M4Muscarinic Acetylcholine Receptors in the Antipsychotic-like Effects of the M1/M4Preferring Muscarinic Receptor Agonist Xanomeline

Dencker, D., Wörtwein, G., Weikop, P., Jeon, J., Thomsen, M., Sager, T. N., Mørk, A., Woldbye, D. P. D., Wess, J., & Fink‐Jensen, A. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.0370-11.2011 · Cited by 65 · see citing works

Locomotion and stereotypy induced by scopolamine: contributions of muscarinic receptors near the pedunculopontine tegmental nucleus

Mathur, A., Shandarin, A., Laviolette, S. R., Parker, J. L., & Yeomans, J. S. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00928-1 · Cited by 65 · see citing works

Development of M 1 mAChR Allosteric and Bitopic Ligands: Prospective Therapeutics for the Treatment of Cognitive Deficits

Davie, B. J., Christopoulos, A., & Scammells, P. J. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn400086m · Cited by 64 · see citing works

Efficacy of Xanomeline in Alzheimer Disease: Cognitive Improvement Measured Using the Computerized Neuropsychological Test Battery (CNTB)

Veroff, A. E., Bodick, N. C., Offen, W., Sramek, J. J., & Cutler, N. R. (1998) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199812000-00010 · Cited by 64 · see citing works

Schizophrenia: Treatment Targets Beyond Monoamine Systems

Ibrahim, H. M., & Tamminga, C. A. (2011) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105851 · Cited by 62 · see citing works

The M1/M4 preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia

Barak, S., & Weiner, I. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710001549 · Cited by 60 · see citing works

Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey

Vardigan, J. D., Cannon, C. E., Puri, V., Dancho, M., Koser, A. J., Wittmann, M., Kuduk, S. D., Renger, J. J., & Uslaner, J. M. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3813-x · Cited by 59 · see citing works

Validation and pharmacological characterisation of MK-801-induced locomotor hyperactivity in BALB/C mice as an assay for detection of novel antipsychotics

Bradford, A. M., Savage, K. M., Jones, D. N. C., & Kalinichev, M. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1938-0 · Cited by 59 · see citing works

Association of Muscarinic M1 Receptor Genetic Polymorphisms with Psychiatric Symptoms and Cognitive Function in Schizophrenic Patients

Liao, D., Hong, C., Chen, H., et al. (2003) · Neuropsychobiology · doi:10.1159/000072880 · Cited by 57 · see citing works

An allosteric enhancer of M4 muscarinic acetylcholine receptor function inhibits behavioral and neurochemical effects of cocaine

Dencker, D., Weikop, P., Sørensen, G., Woldbye, D. P. D., Wörtwein, G., Wess, J., & Fink‐Jensen, A. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2751-8 · Cited by 56 · see citing works

Cognitive deficits in clinical and familial high risk groups for psychosis are common as in first episode schizophrenia

Üçok, A., Direk, N., Koyuncu, A., et al. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.10.030 · Cited by 56 · see citing works

Anticholinergics in the era of atypical antipsychotics: short-term or long-term treatment?

Desmarais, J. E., Beauclair, L., & Margolese, H. C. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112447988 · Cited by 55 · see citing works

Effect of anticholinergic medication on positive and negative symptoms in medication-free schizophrenic patients

Tandon, R., Mann, N. A., Eisner, W. H., et al. (1990) · Psychiatry Research · doi:10.1016/0165-1781(90)90092-j · Cited by 55 · see citing works

Temporal relationship between change in cognition and change in functioning in schizophrenia

Fiszdon, J. M., Choi, J., Goulet, J. L., & Bell, M. D. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.06.010 · Cited by 53 · see citing works

M2/M4 muscarinic receptor binding in the anterior cingulate cortex in schizophrenia and mood disorders

Zavitsanou, K., Katsifis, A. G., Yu, Y., & Huang, X. (2005) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2005.02.007 · Cited by 53 · see citing works

Putative cognitive enhancers in preclinical models related to schizophrenia: The search for an elusive target

Barak, S., & Weiner, I. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.03.011 · Cited by 50 · see citing works

No change in cortical muscarinic M2, M3 receptors or [35S]GTPγS binding in schizophrenia

Scarr, E., Keriakous, D., Crossland, N., et al. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.06.038 · Cited by 50 · see citing works

Specific impairments in visuospatial working and short-term memory following low-dose scopolamine challenge in healthy older adults

Thomas, E. H. X., Snyder, P. J., Pietrzak, R. H., Jackson, C. E., Bednar, M. M., & Maruff, P. T. (2008) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2008.04.010 · Cited by 48 · see citing works

Modulation of prepulse inhibition through both M1 and M4 muscarinic receptors in mice

Thomsen, M., Wess, J., Fulton, B. S., Fink‐Jensen, A., & Caine, S. B. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1740-z · Cited by 48 · see citing works

Effects of Selective Activation of M1 and M4 Muscarinic Receptors on Object Recognition Memory Performance in Rats

Galloway, C. R., Lebois, E. P., Shagarabi, S. L., Hernandez, N. A., & Manns, J. R. (2014) · Pharmacology · doi:10.1159/000357682 · Cited by 46 · see citing works

Modeling cholinergic aspects of schizophrenia: Focus on the antimuscarinic syndrome

Barak, S. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.04.006 · Cited by 46 · see citing works

Role of cholinergic receptors in locomotion induced by scopolamine and oxotremorine-M

Chintoh, A. F. (2003) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(03)00196-5 · Cited by 44 · see citing works

Scopolamine Induces Disruption of Latent Inhibition which is Prevented by Antipsychotic Drugs and an Acetylcholinesterase Inhibitor

Barak, S., & Weiner, I. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301208 · Cited by 44 · see citing works

Synthesis and Structure–Activity Relationships of Allosteric Potentiators of the M4 Muscarinic Acetylcholine Receptor

Kennedy, J. P., Bridges, T. M., Gentry, P. R., Brogan, J. T., Kane, A. S., Jones, C. K., Brady, A. E., Shirey-Rice, J. K., Conn, P. J., & Lindsley, C. W. (2009) · ChemMedChem · doi:10.1002/cmdc.200900231 · Cited by 43 · see citing works

Predictive validity of a MK-801-induced cognitive impairment model in mice: Implications on the potential limitations and challenges of modeling cognitive impairment associated with schizophrenia preclinically

Brown, J. W., Rueter, L. E., & Zhang, M. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.11.008 · Cited by 42 · see citing works

Discovery of a selective M4 positive allosteric modulator based on the 3-amino-thieno[2,3-b]pyridine-2-carboxamide scaffold: Development of ML253, a potent and brain penetrant compound that is active in a preclinical model of schizophrenia

Le, U., Melancon, B. J., Bridges, T. M., Vinson, P. N., Utley, T. J., Lamsal, A., Rodriguez, A. L., Venable, D. F., Sheffler, D. J., Jones, C. K., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.10.073 · Cited by 41 · see citing works

Treating Impaired Cognition in Schizophrenia

Ibrahim, H. M., & Tamminga, C. A. (2012) · Current Pharmaceutical Biotechnology · doi:10.2174/138920112800784772 · Cited by 40 · see citing works

Towards an animal model of an antipsychotic drug-resistant cognitive impairment in schizophrenia: scopolamine induces abnormally persistent latent inhibition, which can be reversed by cognitive enhancers but not by antipsychotic drugs

Barak, S., & Weiner, I. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009176 · Cited by 40 · see citing works

Effects of anticholinergic drugs selective for muscarinic receptor subtypes on prepulse inhibition in mice

Ukai, M., Okuda, A., & Mamiya, T. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.03.066 · Cited by 39 · see citing works

Using cholinergic M1 receptor positive allosteric modulators to improve memory via enhancement of brain cholinergic communication

Chambon, C., Jatzke, C., Wegener, N., Gravius, A., & Danysz, W. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.10.011 · Cited by 38 · see citing works

A new automated method to assess the rat recognition memory: Validation of the method

Chambon, C., Wegener, N., Gravius, A., & Danysz, W. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.03.032 · Cited by 37 · see citing works

Three cases of angel's trumpet tea-induced psychosis in adolescent substance abusers

Göpel, C., Laufer, C., & Marcus, A. (2002) · Nordic Journal of Psychiatry · doi:10.1080/08039480252803927 · Cited by 37 · see citing works

Contrasting Effects of Allosteric and Orthosteric Agonists on M1 Muscarinic Acetylcholine Receptor Internalization and Down-regulation

Thomas, R. L., Langmead, C. J., Wood, M. D., & Challiss, R. A. J. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.160242 · Cited by 32 · see citing works

Introduction to Neuropsychopharmacology

Szabadi, E. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03529.x · Cited by 32 · see citing works

Premorbid intelligence and educational level in bipolar and unipolar disorders: A Danish draft board study

Sørensen, H. J., Sæbye, D., Urfer-Parnas, A., Mortensen, E. L., & Parnas, J. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.12.007 · Cited by 31 · see citing works

Levels of [3H]pirenzepine binding in Brodmann's area 6 from subjects with schizophrenia is not associated with changes in the transcription factor SP1 or BACE1

Dean, B., Soulby, A., Evin, G. M., & Scarr, E. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.08.003 · Cited by 30 · see citing works

Acute scopolamine poisoning after sniffing adulterated cocaine

Nogué, S., Sánz, P., Munné, P., et al. (1991) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(91)90028-w · Cited by 30 · see citing works

Muscarinic M1 receptor sequence: Preliminary studies on its effects on cognition and expression

Scarr, E., Sundram, S., Deljo, A., Cowie, T., Gibbons, A. S., Juzva, S., Mackinnon, A. J., Wood, S. J., Testa, R., Pantelis, C., et al. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.02.011 · Cited by 28 · see citing works

Effects of antipsychotic medication on muscarinic M1 receptor mRNA expression in the rat brain

Han, M., Newell, K. A., Zavitsanou, K., et al. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21491 · Cited by 26 · see citing works

N-desmethylclozapine (NDMC) is an antagonist at the human native muscarinic M1 receptor

Thomas, D. R., Dada, A., Jones, G. A., Deisz, R. A., Gigout, S., Langmead, C. J., Werry, T. D., Hendry, N., Hagan, J. J., Davies, C. H., et al. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.02.017 · Cited by 24 · see citing works

Rapacuronium Augments Acetylcholine-induced Bronchoconstriction via Positive Allosteric Interactions at the M3 Muscarinic Receptor

Jooste, E. H., Sharma, A. K., Zhang, Y., et al. (2005) · Anesthesiology · doi:10.1097/00000542-200512000-00014 · Cited by 24 · see citing works

Differential effects of scopolamine and lorazepam on working memory maintenance versus manipulation processes

Mintzer, M. Z., & Griffiths, R. R. (2007) · Cognitive Affective & Behavioral Neuroscience · doi:10.3758/cabn.7.2.120 · Cited by 19 · see citing works

Effects of low‐dose scopolamine on locomotor activity: No dissociation between cognitive and non‐effects

Poorheidari, G., Pratt, J. A., & Dehghani, N. (2002) · Neuroscience Research Communications · doi:10.1002/nrc.10049 · Cited by 19 · see citing works

Agonist-induced down-regulation of the m4 muscarinic acetylcholine receptor occurs without changes in receptor mRNA steady-state levels

Lenz, W., Petrusch, C., Jakobs, K. H., et al. (1994) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf00173020 · Cited by 17 · see citing works

Central anticholinergic syndrome in a pediatric patient following transdermal scopolamine patch placement.

Holland, M. (1992) · PubMed · Cited by 16 · see citing works

Identification of multiple allosteric sites on the M1 muscarinic acetylcholine receptor

Espinoza-Fonseca, M., & Trujillo-Ferrara, J. G. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.10.069 · Cited by 13 · see citing works

Psychosis Induced by Smoking Cessation Clinic Administered Anticholinergic Overload

Clarke, L. A., Cassidy, C. W., Catalano, G., et al. (2004) · Annals of Clinical Psychiatry · doi:10.1080/10401230490487034 · Cited by 13 · see citing works

Dissociating scopolamine-induced disrupted and persistent latent inhibition: stage-dependent effects of glycine and physostigmine

Barak, S., & Weiner, I. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1785-z · Cited by 11 · see citing works

Selective Activation of Muscarinic Acetylcholine Receptors for the Treatment of Schizophrenia

Dean, B. (2012) · Current Pharmaceutical Biotechnology · doi:10.2174/138920112800784970 · Cited by 9 · see citing works

Ligands for the common allosteric site of acetylcholine M2-receptors: development and application

Holzgrabe, U., Bender, W., Cid, H. M. B., et al. (2000) · Pharmaceutica Acta Helvetiae · doi:10.1016/s0031-6865(99)00028-x · Cited by 8 · see citing works

Effects of intensity and type of prepulse stimulus on prepulse inhibition in scopolamine treated rats

Andrus, A. K., Marable, B. R., Dunbar, G. L., et al. (2007) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2007.06.004 · Cited by 7 · see citing works

Psychosis From Anticholinergic Medications Administered at a Smoking Cessation Clinic

Minton, J. A., Tofade, T. S., Shah, S. A., et al. (2009) · Journal of Pharmacy Practice · doi:10.1177/0897190008330201 · Cited by 4 · see citing works

Cholinergic mechanisms in schizophrenia: Relationship to sleep-EEG abnormalities and positive/ negative symptoms

Tandon, R., Shipley, J. E., Goodson, J. A., et al. (1993) · Schizophrenia Research · doi:10.1016/0920-9964(93)90581-3 · Cited by 3 · see citing works

Oxytocin pathway gene networks in the human brain

Quintana, D. S., Rokicki, J., van der Meer, D., Alnæs, D., Kaufmann, T., Córdova-Palomera, A., Dieset, I., Andreassen, O. A., & Westlye, L. T. (2019) · Nature Communications · doi:10.1038/s41467-019-08503-8 · Cited by 354 · see citing works

Fine Tuning Muscarinic Acetylcholine Receptor Signaling Through Allostery and Bias

van der Westhuizen, E. T., Choy, K. H. C., Valant, C., McKenzie-Nickson, S., Bradley, S. J., Tobin, A. B., Sexton, P. M., & Christopoulos, A. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.606656 · Cited by 63 · see citing works

Muscarinic M1 Receptor Overstimulation Disrupts Working Memory Activity for Rules in Primate Prefrontal Cortex

Vijayraghavan, S., Major, A. J., & Everling, S. (2018) · Neuron · doi:10.1016/j.neuron.2018.05.027 · Cited by 51 · see citing works

The use of muscarinic toxins in the study of muscarinic receptors

Jerusalinsky, D. A., Harvey, A. R., Karlsson, E., et al. (1997) · Life Sciences · doi:10.1016/s0024-3205(97)00061-1 · Cited by 7 · see citing works

Autoradiographic Localization of Muscarinic Receptors in the Gut

Buckley, N. J. (1985) · Springer eBooks · doi:10.1007/978-3-642-70668-4_1 · Cited by 4 · see citing works

Pharmacological characterization of muscarinic acetylcholine binding sites in human and bovine cerebral microvessels

Linville, D., & Hamel, É. (1995) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf00176772 · Cited by 29 · see citing works

Muscarinic Acetylcholine Receptors

Wess, J. (2007) · Wiley eBooks · doi:10.1002/9780470101001.hcn005 · Cited by 4 · see citing works

Toxins from mamba venoms: small proteins with selectivities for different subtypes of muscarinic acetylcholine receptors

Jerusalinsky, D. A., & Harvey, A. L. (1994) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(94)90092-2 · Cited by 87 · see citing works